Immunex Corporation

Syntimmune, Inc.

The Brigham and Women's Hospital, Inc.

Polytherics Limited

Tasrif Pharmaceutical, LLC

Abzena (UK) Limited

Arron Hearn

Robert George Edward Holgate

Richard S Blumberg

Susan Dana Jones

Timothy Gareth Jones

Jay Rothstein

Laurence J Blumberg

Derry Roopenian

Robert G Holgate

Robert George E Holgate

Yu-Hwa Huang

Monica Bertagnolli

Amit Gandhi

Aftab S Karim

Charles Yoon

Timothy David Jones

Provided herein are recombinant antibodies and antigen-binding fragments thereof useful for binding to and inhibiting carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1). Also provided are methods of using the disclosed CEACAM1 antibodies and antigen-binding fragments thereof for reducing T-cell tolerance and for the treatment of cancer.

Humanized and affinity-matured anti-CEACAM1 antibodies

Improved anti-CD154 antibodies are provided herein which have improved therapeutic potency, in vivo half-life and ablated FcR binding and/or complement binding/activation. The use of these antibodies for inducing tolerance and treating immune diseases including autoimmunity, inflammation, transplant recipients, fibrosis and allergic disorders is disclosed herein.

Methods of immunosuppression comprising administering an anti-CD154 antibody

A humanized antibody to the poliovirus receptor can be used to target nucleic acids, proteins, and chemicals to brain cancer cells, thus providing treatment for tumors that are otherwise hard to treat due to the difficulty of getting treatments through the blood brain barrier.

Antibodies and antibody fragments against the CD155 receptor and methods of use thereof

An antibody or antigen-binding portion thereof which binds to PSMA and comprises a heavy chain variable domain comprising the sequences: CDR1: EYTIH (SEQ ID NO: 33) CDR2: NINPNXGGTTYNQKFED (SEQ ID NO: 34) CDR3: XDY (SEQ ID NO: 35) wherein Xis N or Q, and Xis YWLF (SEQ ID NO: 39), GWTF (SEQ ID NO: 40) or AWTM (SEQ ID NO: 41), and wherein if Xis GWTF (SEQ ID NO: 40) or AWTM (SEQ ID NO: 41), the amino acid residue at position H94 in the heavy chain variable region, based on Kabat numbering, is G; and if Xis YWLF (SEQ ID NO: 39), the amino acid residue at position H94 in the heavy chain variable region, based on Kabat numbering, is A. The invention also provides compounds that include the antibody or antigen-binding portion thereof, such as conjugates, and their use in the treatment or diagnosis of disease, in particular cancers, particularly prostate cancer.

Anti-PSMA antibodies, uses thereof and conjugates thereof

Anti-CD154 antibody having improved binding, functional and safety characteristics

Provided herein are recombinant antibodies and antigen-binding portions thereof useful for binding to FcRn and blocking binding of FcRn to human serum albumin. The FcRn-binding proteins can be used to treat a variety of disorders including acute and chronic toxic exposure.

Humanized affinity matured anti-FcRn antibodies

Provided herein are recombinant antibodies and antigen-binding portions thereof useful for binding to FcRn and blocking binding of FcRn to IgG Fc. The FcRn-binding proteins can be used to treat a variety of disorders including autoimmune disorders.

Growing community of inventors

Ely, United Kingdom

Arron Hearn